Mobile website
Basic Research
Effect of silencing FBXO2 expression on proliferation, invasion, migration, and EMT of gastric cancer cells
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To explore the expression of F-box only protein 2 (FBXO2) gene in human gastric cancer cell lines, and its effect on the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) of gastric cancer cells.Methods: Gastric cancer cell lines (MGC-803, AGS, SGC-7901, MKN-28) and normal gastric epithelial cell line GES-1 were selected for this study; and Real-time quantitative PCR (qPCR) was used to detected the expression level of FBXO2 mRNA in the five cell lines. Designed a specific siRNA to inhibit the expression of FBXO2 and transiently transfected into MGC-803 call, and set up a negative control group for transfection of siRNA nonsense sequences. qPCR was used to detect the expression level of FBXO2 mRNA in MGC-803 cells 48 h after transfection; MTT, wound scratch, and Transwell assays were used to detect the effects of FBXO2 down-regulation on cell proliferation, migration and invasion, and WB was used to detect the expression of EMT-related proteins E-cadherin, N-cadherin and vimentin in cells.Results: The expression level of FBXO2 mRNA in the four gastric cancer cell lines was significantly higher than that in gastric epithelial cell line GES-1 (P<0.05 or P<0.01). Compared with the negative control group, FBXO2 mRNA expression in the siRNA-FBXO2 group was decreased (P<0.01), and the proliferation, migration and invasion of the cells were significantly inhibited (P<0.05 or P<0.01), and E-cadherin protein expression was significantly increased (P<0.01), while N-cadherin and vimentin protein expression were significantly decreased (all P<0.01). Conclusion: The low expression of FBXO2 can efficiently inhibited the proliferation, migration and invasion of gastric cancer cells, which might be related with EMT.
Keywords:
Project Supported:
Project supported by Osaikang Hospital Pharmaceutica Foundation of Jiangsu Pharmaceutical Association（No.A201946）
Clc Number:
